These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
35. A simple test for scopolamine mydriasis. Larson MD Anesth Analg; 1991 Dec; 73(6):824. PubMed ID: 1796980 [No Abstract] [Full Text] [Related]
36. Psychosis due to transdermally administered scopolamine. MacEwan GW; Remick RA; Noone JA CMAJ; 1985 Sep; 133(5):431-2. PubMed ID: 4027811 [No Abstract] [Full Text] [Related]
37. Transdermal scopolamine as a cause of transient psychosis in two elderly patients. Mego DM; Omori JM; Hanley JF South Med J; 1988 Mar; 81(3):394-5. PubMed ID: 3347867 [TBL] [Abstract][Full Text] [Related]
38. Delayed hypersensitivity to scopolamine in transdermal therapeutic systems. van der Willigen AH; Oranje AP; Stolz E; van Joost T J Am Acad Dermatol; 1988 Jan; 18(1 Pt 1):146-7. PubMed ID: 3346401 [No Abstract] [Full Text] [Related]
39. Toxic psychosis from transdermal scopolamine in a child. Sennhauser FH; Schwarz HP Lancet; 1986 Nov; 2(8514):1033. PubMed ID: 2877187 [No Abstract] [Full Text] [Related]
40. Results of a randomized double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis. Longo DL; Wesley M; Howser D; Hubbard SM; Anderson T; Young RC Cancer Treat Rep; 1982 Nov; 66(11):1975-6. PubMed ID: 6890407 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]